CN102014958A - 用于治疗的gm-csf和il-17抑制剂 - Google Patents

用于治疗的gm-csf和il-17抑制剂 Download PDF

Info

Publication number
CN102014958A
CN102014958A CN2009801155219A CN200980115521A CN102014958A CN 102014958 A CN102014958 A CN 102014958A CN 2009801155219 A CN2009801155219 A CN 2009801155219A CN 200980115521 A CN200980115521 A CN 200980115521A CN 102014958 A CN102014958 A CN 102014958A
Authority
CN
China
Prior art keywords
amino acid
seq
acid sequence
csf
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801155219A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯蒂娜·普莱特-齐贝克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Micromet GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet GmbH filed Critical Micromet GmbH
Publication of CN102014958A publication Critical patent/CN102014958A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
CN2009801155219A 2008-04-29 2009-04-28 用于治疗的gm-csf和il-17抑制剂 Pending CN102014958A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12588008P 2008-04-29 2008-04-29
US61/125,880 2008-04-29
PCT/EP2009/055129 WO2009133103A1 (en) 2008-04-29 2009-04-28 Inhibitors of gm-csf and il-17 for therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410267649.XA Division CN104338136A (zh) 2008-04-29 2009-04-28 用于治疗的gm-csf和il-17抑制剂

Publications (1)

Publication Number Publication Date
CN102014958A true CN102014958A (zh) 2011-04-13

Family

ID=40810025

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801155219A Pending CN102014958A (zh) 2008-04-29 2009-04-28 用于治疗的gm-csf和il-17抑制剂
CN201410267649.XA Pending CN104338136A (zh) 2008-04-29 2009-04-28 用于治疗的gm-csf和il-17抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410267649.XA Pending CN104338136A (zh) 2008-04-29 2009-04-28 用于治疗的gm-csf和il-17抑制剂

Country Status (16)

Country Link
US (1) US9353180B2 (enExample)
EP (1) EP2279001B1 (enExample)
JP (1) JP5771140B2 (enExample)
KR (2) KR20160117643A (enExample)
CN (2) CN102014958A (enExample)
AU (1) AU2009242088B2 (enExample)
BR (1) BRPI0911469A8 (enExample)
CA (1) CA2717987C (enExample)
EA (1) EA024654B1 (enExample)
ES (1) ES2557494T3 (enExample)
IL (1) IL209028A (enExample)
MX (1) MX2010011309A (enExample)
NZ (1) NZ587865A (enExample)
UA (1) UA102097C2 (enExample)
WO (1) WO2009133103A1 (enExample)
ZA (1) ZA201006353B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111690063A (zh) * 2020-05-25 2020-09-22 北京大学 一种抗gm-csf纳米抗体及其制备方法和应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120164101A1 (en) * 2009-04-30 2012-06-28 Jacques Galipeau Gm-csf and interleukin-21 conjugates and uses thereof in the modulation of immune response and treatment of cancer
US20140044731A1 (en) * 2011-01-04 2014-02-13 Robert Nussenblatt Methods of treating age-related macular degeneration
BR112013033944A2 (pt) 2011-07-06 2017-12-19 Morphosys Ag combinação sinérgica
US9901079B2 (en) 2011-08-18 2018-02-27 New York University Inhibition of oncogenic kras-induced GM-CSF production and function
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
RU2714919C2 (ru) 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1711282A (zh) * 2002-10-30 2005-12-21 健泰科生物技术公司 Il－17产生的抑制
WO2006066088A2 (en) * 2004-12-16 2006-06-22 Genentech, Inc. Methods for treating autoimmune disorders
WO2006111353A2 (en) * 2005-04-18 2006-10-26 Micromet Ag Antibody neutralizers of human granulocyte macrophage colony stimulating factor
CN101001645A (zh) * 2004-08-05 2007-07-18 诺瓦提斯公司 Il－17拮抗抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
KR101395515B1 (ko) * 2006-02-08 2014-05-14 모르포테크, 인크. 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1711282A (zh) * 2002-10-30 2005-12-21 健泰科生物技术公司 Il－17产生的抑制
CN101001645A (zh) * 2004-08-05 2007-07-18 诺瓦提斯公司 Il－17拮抗抗体
WO2006066088A2 (en) * 2004-12-16 2006-06-22 Genentech, Inc. Methods for treating autoimmune disorders
WO2006111353A2 (en) * 2005-04-18 2006-10-26 Micromet Ag Antibody neutralizers of human granulocyte macrophage colony stimulating factor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NUMASAKI M，ET AL: "Interleukin-17 promotes angiogenesis and tumor growth", 《BLOOD》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111690063A (zh) * 2020-05-25 2020-09-22 北京大学 一种抗gm-csf纳米抗体及其制备方法和应用

Also Published As

Publication number Publication date
ZA201006353B (en) 2015-04-29
UA102097C2 (ru) 2013-06-10
AU2009242088A1 (en) 2009-11-05
US20110104172A1 (en) 2011-05-05
EA201001496A1 (ru) 2011-06-30
KR101681331B1 (ko) 2016-12-01
CA2717987A1 (en) 2009-11-05
ES2557494T3 (es) 2016-01-26
BRPI0911469A8 (pt) 2017-12-05
NZ587865A (en) 2012-06-29
JP2011518857A (ja) 2011-06-30
BRPI0911469A2 (pt) 2016-04-26
IL209028A (en) 2015-08-31
IL209028A0 (en) 2011-01-31
KR20100135937A (ko) 2010-12-27
WO2009133103A1 (en) 2009-11-05
JP5771140B2 (ja) 2015-08-26
CN104338136A (zh) 2015-02-11
CA2717987C (en) 2018-11-13
EP2279001B1 (en) 2015-09-30
EP2279001A1 (en) 2011-02-02
MX2010011309A (es) 2010-12-14
KR20160117643A (ko) 2016-10-10
US9353180B2 (en) 2016-05-31
AU2009242088B2 (en) 2014-08-21
EA024654B1 (ru) 2016-10-31

Similar Documents

Publication Publication Date Title
JP5771140B2 (ja) 治療用のｇｍ−ｃｓｆおよびｉｌ−１７阻害剤
JP7324565B2 (ja) Ｃｄ１２７に対する抗体
KR102326482B1 (ko) 피부과학적 병리의 치료
JP6861301B2 (ja) 移植片拒絶の予防に使用するための抗ｃｄ４０抗体
US20190048055A1 (en) Alt-803 in combination with anti-cd38 antibody for cancer therapies
US20120201821A1 (en) Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
EP3829636A1 (en) Use of glucagon receptor antagonists with immunotherapeutic agent
WO2010132683A1 (en) Methods and compositions for treating lupus
RU2539034C2 (ru) Лечение рассеянного склероза
US12209124B2 (en) Anti-IL-17A antibody and use thereof
EP2373339B1 (en) A b cell depleting agent for the treatment of atherosclerosis
EP4006053A1 (en) Method for treating autoimmune disease by il-17 antagonist
WO2025221933A9 (en) Antibodies and polypeptides comprising variant fc regions
TW202130364A (zh) 以介白素２４或介白素２０拮抗劑治療組織纖維化和／或損傷和／或器官衰竭
Doll Development of therapeutic proteins for the treatment of rheumatoid arthritis and chronic cardiac rejection
EP0406880A2 (en) Method for stimulating macrophage activity against tumors and composition therefor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Munich, Germany

Applicant after: Amgen Research Munich GmbH

Address before: Munich, Germany

Applicant before: Micromet AG

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: MICROMET AG TO: AMGEN RESEARCH MUNICH GMBH

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110413